Severe acute respiratory syndrome (SARS) emerged as a new human infection in South China in 2002, and ultimately caused over 8,000 infections and almost 800 deaths as it spread to five continents along airline routes. While the overall mortality rate from SARS during the 2002-03 pandemic was approximately 10 percent, the mortality among the elderly exceeded 50 percent. Subsequent outbreaks were reported later in 2003 with the latest outbreak in 2004 in China occurring as a result of accidental exposure in a laboratory.
In May 2012, Baylor College of Medicine (BCM) announced that they will receive up to $6.2 million over five years from the National Institute Of Allergy and Infectious Diseases, to develop a vaccine for severe acute respiratory syndrome (SARS). The research and development will be done in partnership with the Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development.
Through a recent award obtained by Baylor College of Medicine, the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) will collaborate as part of a consortiom with key partners at the New York Blood Center, University of Texas Medical Branch, Immune Design Corporation and Walter Reed Army Institute of Re
Dr. Gershon Honored for her Pivotal Role in Combating Chickenpox